FDA inspection
Zhejiang Haisen Pharmaceutical Co., Ltd.: FDA inspection ending Nov 15, 2024
FDA inspection 1255806 · Voluntary Action Indicated (VAI) · Dongyang
Key facts
| Inspection ID | 1255806 |
|---|---|
| Firm | Zhejiang Haisen Pharmaceutical Co., Ltd. |
| FEI number | 3003967524 |
| Address | Xianzhuang, Weishanzhen Dongyang |
| City | Dongyang |
| Country | China |
| Fiscal year | 2025 |
| Inspection end date | Nov 15, 2024 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data